Tetracyclines for multidrug-resistant Acinetobacter baumannii infections

Falagas, Matthew E.; Vardakas, Konstantinos Z.; Kapaskelis, Anastasios; Triarides, Nikolaos A.; Roussos, N.

doi:10.1016/j.ijantimicag.2014.12.031

Cited by 55 publications

(46 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This might be explained to some extent by the ability of minocycline to thwart AdeABC efflux, and a lower rate of minocycline-resistance development in A. baumannii (Lomovskaya et al 2014). Clinical responses to Minocin IV used as a monotherapy or in combination for the treatment of MDR A. baumannii infections appear encouraging (Goff et al 2014;Ritchie and Garavaglia-Wilson 2014;Falagas et al 2015), but this therapy will likely be a stop-gap as the spread of RPPs should increase minocycline resistance. A. baumannii RND AdeABC: tetracycline, tigecycline, minocycline, a doxycycline a AdeDE: tetracycline AdeFGH: tetracycline, minocycline, tigecycline AdeIJK: tetracycline, minocycline, doxycycline, tigecycline Chau et al 2004;Ruzin et al 2007;Damier-Piolle et al 2008;Coyne et al 2010Coyne et al , 2011Ruzin et al 2010;Lomovskaya et al 2014Lomovskaya et al , 2015 B. fragilis RND BmeABC: tetracycline Pumbwe et al 2006 E. coli RND AcrAB: tetracycline, tigecycline, minocycline, doxycycline AcrEF: tetracycline, tigecycline, minocycline, doxycycline Hirata et al 2004 Enterobacter spp.…”

Section: The Present and Future For Tetracyclines Minocyclinementioning

confidence: 99%

Tetracycline Antibiotics and Resistance

Grossman

2016

Cold Spring Harb Perspect Med

458

345

View full text Add to dashboard Cite

Section: The Present and Future For Tetracyclines Minocyclinementioning

confidence: 99%

Tetracycline Antibiotics and Resistance

Grossman

2016

Cold Spring Harb Perspect Med

458

345

View full text Add to dashboard Cite

“…Multidrug-resistant Acinetobacter baumannii infections posed a serious health trouble all over the world (36,37). Even though, the overall prevalence (4.95%) was not considerably high, our review assured that resistance to multiple antibiotics was also a great concern for Eastern Africa (87.3%).…”

Section: Discussionmentioning

confidence: 80%

Therapeutic Challenges of Multidrug Resistant Acinetobacter baumannii in Eastern Africa: Systematic Review

Geteneh

Demissew

Adimas

et al. 2019

Preprint

View full text Add to dashboard Cite

Acinetobacter baumannii, an opportunistic gram negative bacterium, is known to emerge as a major health threat in Eastern Africa. Clinical isolates exhibit resistance to carbapenems and most or all available antibiotics. This review is intended to present concerns about resistance and therapeutic challenges of multi drug resistance Acinetobacter baumannii in Eastern Africa. Data was obtained from PubMed and Google scholar, and from free goggle access and web Medline for facts about Acinetobacter baumannii and its resistance pattern. Moreover, PreferredReporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flow chart was used to guide the selection of study materials. Total of 98 articles identified, 13 fit the criteria and were included for the final analysis. In East Africa the overall prevalence of Acinetobacter baumannii was 4.95%, while the overall rate of multi drug resistance, carbapenem and pan resistance was 87.3%, 64.8% and 25.2% respectively. Colistin resurges as potential therapeutic options to overcome the lack of new antibiotic treatment of Acinetobacter baumannii. There needs a collaborative effort in researches targeted for Acinetobacter baumannii treatment and respond for call of "Research and Development of new antibiotics" to control its damning impact.

show abstract

“…Minocycline has emerged as the tetracycline of choice for multidrug-resistant Acinetobacter baumannii infections, although doxycycline has also demonstrated activity. The use of tetracyclines for A baumannii infections was recently reviewed [ 16 ].…”

Section: Tetracycline Overviewmentioning

confidence: 99%